This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Apr 2;299(13):1598-600.

doi: 10.1001/jama.299.13.1598.

Newly approved does not always mean new and improved

Geoffrey M Anderson¹, David Juurlink, Allan S Detsky

Affiliations

PMID: 18387934
DOI: 10.1001/jama.299.13.1598

Newly approved does not always mean new and improved

Geoffrey M Anderson et al. JAMA. 2008.

. 2008 Apr 2;299(13):1598-600.

doi: 10.1001/jama.299.13.1598.

Authors

Geoffrey M Anderson¹, David Juurlink, Allan S Detsky

Affiliation

¹ Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

PMID: 18387934
DOI: 10.1001/jama.299.13.1598

No abstract available

PubMed Disclaimer

Similar articles

Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
French JA. French JA. Epilepsia. 2002 Sep;43(9):951-5. doi: 10.1046/j.1528-1157.2002.24302.x. Epilepsia. 2002. PMID: 12199719 No abstract available.
Withdrawing FDA approval of midodrine after marketing.
Holtzman NA, Starfield B. Holtzman NA, et al. JAMA. 2011 Feb 23;305(8):781-2; author reply 782. doi: 10.1001/jama.2011.161. JAMA. 2011. PMID: 21343575 No abstract available.
Manufacturing uncertainty: adverse effects of drug development for women.
Peppin P. Peppin P. Int J Law Psychiatry. 2003 Sep-Oct;26(5):515-32. doi: 10.1016/S0160-2527(03)00084-0. Int J Law Psychiatry. 2003. PMID: 14522223 No abstract available.
Postmarketing surveillance and reporting of adverse drug events.
Baer RK. Baer RK. S D J Med. 2004 Jan;57(1):13-4. S D J Med. 2004. PMID: 14964975 Review. No abstract available.
Commentary by a child psychiatrist in industry on the assessment of drug safety.
Allen AJ. Allen AJ. J Child Adolesc Psychopharmacol. 2007 Jun;17(3):288-91. doi: 10.1089/cap.2007.0031. J Child Adolesc Psychopharmacol. 2007. PMID: 17630860 Review. No abstract available.

See all similar articles

Cited by

Adoption of new drugs by physicians: a survival analysis.
Garjón FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Garjón FJ, et al. BMC Health Serv Res. 2012 Mar 8;12:56. doi: 10.1186/1472-6963-12-56. BMC Health Serv Res. 2012. PMID: 22401169 Free PMC article.
Off-label prescribing: a call for heightened professional and government oversight.
Dresser R, Frader J. Dresser R, et al. J Law Med Ethics. 2009 Fall;37(3):476-86, 396. doi: 10.1111/j.1748-720X.2009.00408.x. J Law Med Ethics. 2009. PMID: 19723258 Free PMC article.
Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Zou CX, et al. Trials. 2018 Oct 23;19(1):581. doi: 10.1186/s13063-018-2957-0. Trials. 2018. PMID: 30352601 Free PMC article.
Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology.
Deyo RA. Deyo RA. Perm J. 2009 Spring;13(2):71-6. doi: 10.7812/TPP/08-087. Perm J. 2009. PMID: 21373235 Free PMC article. No abstract available.
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Downing NS, et al. JAMA. 2014 Jan 22-29;311(4):368-77. doi: 10.1001/jama.2013.282034. JAMA. 2014. PMID: 24449315 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems